Science
Trump Administration Slashes Research Into L.G.B.T.Q. Health
The Trump administration has scrapped more than $800 million worth of research into the health of L.G.B.T.Q. people, abandoning studies of cancers and viruses that tend to affect members of sexual minority groups and setting back efforts to defeat a resurgence of sexually transmitted infections, according to an analysis of federal data by The New York Times.
In keeping with its deep opposition to both diversity programs and gender-affirming care for adolescents, the administration has worked aggressively to root out research touching on equity measures and transgender health.
But its crackdown has reverberated far beyond those issues, eliminating swaths of medical research on diseases that disproportionately afflict L.G.B.T.Q. people, a group that comprises nearly 10 percent of American adults.
Of the 669 grants that the National Institutes of Health had canceled in whole or in part as of early May, at least 323 — nearly half of them — related to L.G.B.T.Q. health, according to a review by The Times of every terminated grant.
Federal officials had earmarked $806 million for the canceled projects, many of which had been expected to draw more funding in the years to come.
Scores of research institutions lost funding, a list that includes not only White House targets like Johns Hopkins and Columbia, but also public universities in the South and the Midwest, like Ohio State University and the University of Alabama at Birmingham.
At Florida State University, $41 million worth of research was canceled, including a major effort to prevent H.I.V. in adolescents and young adults, who experience a fifth of new infections in the United States each year.
In termination letters over the last two months, the N.I.H. justified the cuts by telling scientists that their L.G.B.T.Q. work “no longer effectuates agency priorities.” In some cases, the agency said canceled research had been “based on gender identity,” which gave rise to “unscientific” results that ignored “biological realities.”
Other termination letters told scientists their studies erred by being “based primarily on artificial and nonscientific categories, including amorphous equity objectives.”
The cuts follow a surge in federal funding for L.G.B.T.Q. research over the past decade, and active encouragement from the N.I.H. for grant proposals focused on sexual and gender minority groups that began during the Obama administration.
President Trump’s allies have argued that the research is shot through with ideological bias.
“There’s been a train of abuses of the science to fit a preconceived conclusion,” said Roger Severino of the Heritage Foundation, the conservative think tank that helped formulate some Trump administration policies.
“And that was based on an unscientific premise that biology is effectively irrelevant, and a political project of trying to mainstream the notion that people could change their sex.”
Scientists said canceling research on such a broad range of illnesses related to sexual and gender minority groups effectively created a hierarchy of patients, some more worthy than others.
“Certain people in the United States shouldn’t be getting treated as second-class research subjects,” said Simon Rosser, a professor at the University of Minnesota whose lab was studying cancer in L.G.B.T.Q. people before significant funding was pulled.
“That, I think, is anyone’s definition of bigotry,” he added. “Bigotry in science.”
The canceled projects are among the most vivid manifestations of a broad dismantling of the infrastructure that has for 80 years supported medical research across the United States.
Beyond terminating studies, federal officials have gummed up the grant-making process by slow-walking payments, delaying grant review meetings and scaling back new grant awards.
Bigger changes may be in store: Mr. Trump on Friday proposed reducing the N.I.H. budget from roughly $48 billion to $27 billion, citing in part what he described as the agency’s efforts to promote “radical gender ideology.”
The legality of the mass terminations is unclear. Two separate lawsuits challenging the revocation of a wide range of grants — one filed by a group of researchers, and the other by 16 states — argued that the Trump administration had failed to offer a legal rationale for the cuts.
The White House and the Department of Health and Human Services did not respond to requests for comment.
Andrew Nixon, a spokesman for the health department, told The Daily Signal, a conservative publication, last month that the move “away from politicized D.E.I. and gender ideology studies” was in “accordance with the president’s executive orders.”
The N.I.H. said in a statement: “N.I.H. is taking action to terminate research funding that is not aligned with N.I.H. and H.H.S. priorities. We remain dedicated to restoring our agency to its tradition of upholding gold-standard, evidence-based science.”
The L.G.B.T.Q. cuts ended studies on antibiotic resistance, undiagnosed autism in sexual minority groups, and certain throat and other cancers that disproportionately affect those groups. Funding losses have led to firings at some L.G.B.T.Q.-focused labs that had only recently been preparing to expand.
The N.I.H. used to reserve grant cancellations for rare cases of research misconduct or possible harm to participants. The latest cuts, far from protecting research participants, are instead putting them in harm’s way, scientists said.
They cited the jettisoning of clinical trials, which have now been left without federal funding to care for volunteer participants.
“We’re stopping things that are preventing suicide and preventing sexual violence,” said Katie Edwards, a professor at the University of Michigan, whose funding for several clinical trials involving L.G.B.T.Q. people was canceled.
H.I.V. research has been hit particularly hard.
The N.I.H. ended several major grants to the Adolescent Medicine Trials Network for H.I.V./AIDS Intervention, a program that had helped lay the groundwork for the use in adolescents of a medication regimen that can prevent infections.
That regimen, known as pre-exposure prophylaxis, or PrEP, is credited with helping beat back the disease in young people.
Cuts to the program have endangered an ongoing trial of a product that would prevent both H.I.V. and pregnancy and a second trial looking at combining sexual health counseling with behavioral therapy to reduce the spread of H.I.V. in young sexual minority men who use stimulants.
Together with the termination of dozens of other H.I.V. studies, the cuts have undermined Mr. Trump’s stated goal from his first term to end the country’s H.I.V. epidemic within a decade, scientists said.
The N.I.H. terminated work on other sexually transmitted illnesses, as well.
Dr. Matthew Spinelli, an infectious disease researcher at the University of California, San Francisco, was in the middle of a clinical trial of doxycycline, a common antibiotic that, taken after sex, can prevent some infections with syphilis, gonorrhea and chlamydia.
The trial was, he said, “as nerdy as it gets”: a randomized study in which participants were given different regimens of the antibiotic to see how it is metabolized.
He hoped the findings would help scientists understand the drug’s effectiveness in women, and also its potential to cause drug resistance, a concern that Secretary of State Marco Rubio had voiced in the past.
But health officials, citing their opposition to research regarding “gender identity,” halted funding for the experiment in March. That left Dr. Spinelli without any federal funding to monitor the half-dozen people who had already been taking the antibiotic.
It also put the thousands of doses that Dr. Spinelli had bought with taxpayer money at risk of going to waste. He said stopping work on diseases like syphilis and H.I.V. would allow new outbreaks to spread.
“The H.I.V. epidemic is going to explode again as a result of these actions,” said Dr. Spinelli, who added that he was speaking only for himself, not his university. “It’s devastating for the communities affected.”
Despite a recent emphasis on the downsides of transitioning, federal officials canceled several grants examining the potential risks of gender-affirming hormone therapy. The projects looked at whether hormone therapy could, for example, increase the risk of breast cancer, cardiovascular disease, altered brain development or H.I.V.
Other terminated grants examined ways of addressing mental illness in transgender people, who now make up about 3 percent of high school students and report sharply higher rates of persistent sadness and suicide attempts.
For Dr. Edwards, of the University of Michigan, funding was halted for a clinical trial looking at how online mentoring might reduce depression and self-harm among transgender teens, one of six studies of hers that were canceled.
Another examined interventions for the families of L.G.B.T.Q. young people to promote more supportive caregiving and, in turn, reduce dating violence and alcohol use among the young people.
The N.I.H. categorizes research only by certain diseases, making it difficult to know how much money the agency devotes to L.G.B.T.Q. health. But a report in March estimated that such research made up less than 1 percent of the N.I.H. portfolio over a decade.
The Times sought to understand the scale of terminated funding for L.G.B.T.Q. medical research by reviewing the titles and, in many cases, research summaries for each of the 669 grants that the Trump administration said it had canceled in whole or in part as of early May.
Beyond grants related to L.G.B.T.Q. people and the diseases and treatments that take a disproportionate toll on them, The Times included in its count studies that were designed to recruit participants from sexual and gender minority groups.
It excluded grants related to illnesses like H.I.V. that were focused on non-L.G.B.T.Q. patients.
While The Times examined only N.I.H. research grants, the Trump administration is also ending or considering ending L.G.B.T.Q. programs elsewhere in the federal health system. It has proposed, for example, scrapping a specialized suicide hotline for L.G.B.T.Q. young people.
The research cuts stand to hollow out a field that in the last decade had not only grown larger, but also come to encompass a wider range of disease threats beyond H.I.V.
Already, scientists said, younger researchers are losing jobs in sexual and gender minority research and scrubbing their online biographies of evidence that they ever worked in the field.
Five grants obtained by Brittany Charlton, a professor at the Harvard School of Public Health, have been canceled, including one looking at sharply elevated rates of stillbirths among L.G.B.T.Q. women.
Ending research on disease threats to gender and sexual minority groups, she said, would inevitably rebound on the entire population. “When other people are sick around you, it does impact you, even if you may think it doesn’t,” she said.
Irena Hwang contributed reporting.
Science
Contributor: With high deductibles, even the insured are functionally uninsured
I recently saw a patient complaining of shortness of breath and a persistent cough. Worried he was developing pneumonia, I ordered a chest X-ray — a standard diagnostic tool. He refused. He hadn’t met his $3,000 deductible yet, and so his insurance would have required him to pay much or all of the cost for that scan. He assured me he would call if he got worse.
For him, the X-ray wasn’t a medical necessity, but it would have been a financial shock he couldn’t absorb. He chose to gamble on a cough, and five days later, he lost — ending up in the ICU with bilateral pneumonia. He survived, but the cost of his “savings” was a nearly fatal hospital stay and a bill that will quite likely bankrupt him. He is lucky he won’t be one of the 55,000 Americans to die from pneumonia each year.
As a physician associate in primary care, I serve as a frontline witness to this failure of the American approach to insurance. Medical professionals are taught that the barrier to health is biology: bacteria, viruses, genetics. But increasingly, the barrier is a policy framework that pressures insured Americans to gamble with their lives. High-deductible health plans seem affordable because their monthly premiums are lower than other plans’, but they create perverse incentives by discouraging patients from seeking and accepting diagnostics and treatments — sometimes turning minor, treatable issues into expensive, life-threatening emergencies. My patient’s gamble with his lungs is a microcosm of the much larger gamble we are taking with the American public.
The economic theory underpinning these high deductibles is known as “skin in the game.” The idea is that if patients are responsible for the first few thousand dollars of their care, they will become savvy consumers, shopping around for the best value and driving down healthcare costs.
But this logic collapses in the exam room. Healthcare is not a consumer good like a television or a used car. My patient was not in a position to “shop around” for a cheaper X-ray, nor was he qualified to determine if his cough was benign or deadly. The “skin in the game” theory assumes a level of medical literacy and market transparency that simply doesn’t exist in a moment of crisis. You can compare the specs of two SUVs; you cannot “shop around” for a life-saving diagnostic while gasping for air.
A 2025 poll from the Kaiser Family Foundation points to this reality, finding that up to 38% of insured American adults say they skipped or postponed necessary healthcare or medications in the past 12 months because of cost. In the same poll, 42% of those who skipped care admitted their health problem worsened as a result.
This self-inflicted public health crisis is set to deteriorate further. The Congressional Budget Office estimates roughly 15 million people will lose health coverage and become uninsured by 2034 because of Medicaid and Affordable Care Act marketplace cuts. That is without mentioning the millions more who will see their monthly premiums more than double if premium tax credits are allowed to expire. If that happens, not only will millions become uninsured but also millions more will downgrade to “bronze” plans with huge deductibles just to keep their premiums affordable. We are about to flood the system with “insured but functionally uninsured” patients.
I see the human cost of this “functional uninsurance” every week. These are patients who technically have coverage but are terrified to use it because their deductibles are so large they may exceed the individuals’ available cash or credit — or even their net worth. This creates a dangerous paradox: Americans are paying hundreds of dollars a month for a card in their wallet they cannot afford to use. They skip the annual physical, ignore the suspicious mole and ration their insulin — all while technically insured. By the time they arrive at my clinic, their disease has often progressed to a catastrophic event, from what could have been a cheap fix.
Federal spending on healthcare should not be considered charity; it is an investment in our collective future. We cannot expect our children to reach their full potential or our workforce to remain productive if basic healthcare needs are treated as a luxury. Inaction by Congress and the current administration to solve this crisis is legislative malpractice.
In medicine, we are trained to treat the underlying disease, not just the symptoms. The skipped visits and ignored prescriptions are merely symptoms; the disease is a policy framework that views healthcare as a commodity rather than a fundamental necessity. If we allow these cuts to proceed, we are ensuring that the American workforce becomes sicker, our hospitals more overwhelmed and our economy less resilient. We are walking willingly into a public health crisis that is entirely preventable.
Joseph Pollino is a primary care physician associate in Nevada.
Insights
L.A. Times Insights delivers AI-generated analysis on Voices content to offer all points of view. Insights does not appear on any news articles.
Viewpoint
Perspectives
The following AI-generated content is powered by Perplexity. The Los Angeles Times editorial staff does not create or edit the content.
Ideas expressed in the piece
-
High-deductible health plans create a barrier to necessary medical care, with patients avoiding diagnostics and treatments due to out-of-pocket cost concerns[1]. Research shows that 38% of insured American adults skipped or postponed necessary healthcare or medications in the past 12 months because of cost, with 42% reporting their health worsened as a result[1].
-
The economic theory of “skin in the game”—which assumes patients will shop around for better healthcare values if they have financial responsibility—fails in medical practice because patients lack the medical literacy to make informed decisions in moments of crisis and cannot realistically compare pricing for emergency or diagnostic services[1].
-
Rising deductibles are pushing enrollees toward bronze plans with deductibles averaging $7,476 in 2026, up from the average silver plan deductible of $5,304[1][4]. In California’s Covered California program, bronze plan enrollment has surged to more than one-third of new enrollees in 2026, compared to typically one in five[1].
-
Expiring federal premium tax credits will more than double out-of-pocket premiums for ACA marketplace enrollees in 2026, creating an expected 75% increase in average out-of-pocket premium payments[5]. This will force millions to either drop coverage or downgrade to bronze plans with massive deductibles, creating a population of “insured but functionally uninsured” people[1].
-
High-deductible plans pose particular dangers for patients with chronic conditions, with studies showing adults with diabetes involuntarily switched to high-deductible plans face 11% higher risk of hospitalization for heart attacks, 15% higher risk for strokes, and more than double the likelihood of blindness or end-stage kidney disease[4].
Different views on the topic
-
Expanding access to health savings accounts paired with bronze and catastrophic plans offers tax advantages that allow higher-income individuals to set aside tax-deductible contributions for qualified medical expenses, potentially offsetting higher out-of-pocket costs through strategic planning[3].
-
Employers and insurers emphasize that offering multiple plan options with varying deductibles and premiums enables employees to select plans matching their individual needs and healthcare usage patterns, allowing those who rarely use healthcare to save money through lower premiums[2]. Large employers increasingly offer three or more medical plan choices, with the expectation that employees choosing the right plan can unlock savings[2].
-
The expansion of catastrophic plans with streamlined enrollment processes and automatic display on HealthCare.gov is intended to make affordable coverage more accessible for certain income groups, particularly those above 400% of federal poverty level who lose subsidies[3].
-
Rising healthcare costs, including specialty drugs and new high-cost cell and gene therapies, are significant drivers requiring premium increases regardless of plan design[5]. Some insurers are managing affordability by discontinuing costly coverage—such as GLP-1 weight-loss medications—to reduce premium rate increases for broader plan members[5].
Science
Trump administration slashes number of diseases U.S. children will be regularly vaccinated against
The U.S. Department of Health and Human Services announced sweeping changes to the pediatric vaccine schedule on Monday, sharply cutting the number of diseases U.S. children will be regularly immunized against.
Under the new guidelines, the U.S. still recommends that all children be vaccinated against measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Haemophilus influenzae type B (Hib), pneumococcal disease, human papillomavirus (HPV) and varicella, better known as chickenpox.
Vaccines for all other diseases will now fall into one of two categories: recommended only for specific high-risk groups, or available through “shared clinical decision-making” — the administration’s preferred term for “optional.”
These include immunizations for hepatitis A and B, rotavirus, respiratory syncytial virus (RSV), bacterial meningitis, influenza and COVID-19. All these shots were previously recommended for all children.
Insurance companies will still be required to fully cover all childhood vaccines on the CDC schedule, including those now designated as optional, according to the Department of Health and Human Services.
Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, said in a statement that the new schedule “protects children, respects families, and rebuilds trust in public health.”
But pediatricians and public health officials widely condemned the shift, saying that it would lead to more uncertainty for patients and a resurgence of diseases that had been under control.
“The decision to weaken the childhood immunization schedule is misguided and dangerous,” said Dr. René Bravo, a pediatrician and president of the California Medical Assn. “Today’s decision undermines decades of evidence-based public health policy and sends a deeply confusing message to families at a time when vaccine confidence is already under strain.”
The American Academy of Pediatrics condemned the changes as “dangerous and unnecessary,” and said that it will continue to publish its own schedule of recommended immunizations. In September, California, Oregon, Washington and Hawaii announced that those four states would follow an independent immunization schedule based on recommendations from the AAP and other medical groups.
The federal changes have been anticipated since December, when President Trump signed a presidential memorandum directing the health department to update the pediatric vaccine schedule “to align with such scientific evidence and best practices from peer, developed countries.”
The new U.S. vaccination guidelines are much closer to those of Denmark, which routinely vaccinates its children against only 10 diseases.
As doctors and public health experts have pointed out, Denmark also has a robust system of government-funded universal healthcare, a smaller and more homogenous population, and a different disease burden.
“The vaccines that are recommended in any particular country reflect the diseases that are prevalent in that country,” said Dr. Kelly Gebo, dean of the Milken Institute School of Public Health at George Washington University. “Just because one country has a vaccine schedule that is perfectly reasonable for that country, it may not be at all reasonable” elsewhere.
Almost every pregnant woman in Denmark is screened for hepatitis B, for example. In the U.S., less than 85% of pregnant women are screened for the disease.
Instead, the U.S. has relied on universal vaccination to protect children whose mothers don’t receive adequate care during pregnancy. Hepatitis B has been nearly eliminated in the U.S. since the vaccine was introduced in 1991. Last month, a panel of Kennedy appointees voted to drop the CDC’s decades-old recommendation that all newborns be vaccinated against the disease at birth.
“Viruses and bacteria that were under control are being set free on our most vulnerable,” said Dr. James Alwine, a virologist and member of the nonprofit advocacy group Defend Public Health. “It may take one or two years for the tragic consequences to become clear, but this is like asking farmers in North Dakota to grow pineapples. It won’t work and can’t end well.”
Science
For Oprah Winfrey, a croissant is now just a croissant — not a struggle
Yes, Oprah Winfrey has discussed her weight loss and weight gain and weight in general before — many, many times before. The difference this time around, she says, is how little food noise there is in her daily life, and how little shame. It’s so quiet, in fact, that she can eat a whole croissant and simply acknowledge she had breakfast.
“Food noise,” for those who don’t experience it, is a virtually nonstop mental conversation about food that, according to Tufts Medicine, rarely shuts up and instead drives a person “to eat when they’re not hungry, obsess over meals and feel shame or guilt about their eating habits.”
“This type of obsessive food-related thinking can override hunger cues and lead to patterns of overeating, undereating or emotional eating — especially for people who are overweight,” Tufts said.
Winfrey told People in an exclusive interview published Tuesday that in the past she would have been thinking, “‘How many calories in that croissant? How long is it going to take me to work it off? If I have the croissant, I won’t be able to have dinner.’ I’d still be thinking about that damn croissant!”
What has changed is her acceptance 2½ years ago that she has a disease, obesity, and that this time around there was something not called “willpower” to help her manage it.
The talk show host has been using Mounjaro, one of the GLP-1 drugs, since 2023. The weight-loss version of Mounjaro is Zepbound, like Wegovy is the weight-loss version of Ozempic. Trulicity and Victroza are also GLP-1s, and a pill version of Wegovy was just approved by the FDA.
When she started using the injectable, Winfrey told People she welcomed the arrival of a tool to help her get away from the yo-yo path she’d been on for decades. After understanding the science behind it, she said, she was “absolutely done with the shaming from other people and particularly myself” after so many years of weathering public criticism about her weight.
“I have been blamed and shamed,” she said elsewhere in that 2023 interview, “and I blamed and shamed myself.”
Now, on the eve of 2026, Winfrey says her mental shift is complete. “I came to understand that overeating doesn’t cause obesity. Obesity causes overeating,” she told the outlet. “And that’s the most mind-blowing, freeing thing I’ve experienced as an adult.”
She isn’t even sharing her current weight with the public.
Winfrey did take a break from the medication early in 2024, she said, and started to regain weight despite continuing to work out and eat healthy foods. So for Winfrey the obesity prescription will be renewed for a lifetime. C’est la vie seems to be her attitude.
“I’m not constantly punishing myself,” she said. “I hardly recognize the woman I’ve become. But she’s a happy woman.”
Winfrey has to take a carefully managed magnesium supplement and make sure she drinks enough water, she said. The shots are done weekly, except when she feels like she can go 10 or 12 days. But packing clothes for the Australian leg of her “Enough” book tour was an off-the-rack delight, not a trip down a shame spiral. She’s even totally into regular exercise.
Plus along with the “quiet strength” she has found in the absence of food noise, Winfrey has experienced another cool side effect: She pretty much couldn’t care less about drinking alcohol.
“I was a big fan of tequila. I literally had 17 shots one night,” she told People. “I haven’t had a drink in years. The fact that I no longer even have a desire for it is pretty amazing.”
So back to that croissant. How did she feel after she scarfed it down?
“I felt nothing,” she said. “The only thing I thought was, ‘I need to clean up these crumbs.’”
-
World1 week agoHamas builds new terror regime in Gaza, recruiting teens amid problematic election
-
Indianapolis, IN1 week agoIndianapolis Colts playoffs: Updated elimination scenario, AFC standings, playoff picture for Week 17
-
News1 week agoFor those who help the poor, 2025 goes down as a year of chaos
-
World1 week agoPodcast: The 2025 EU-US relationship explained simply
-
Business1 week agoInstacart ends AI pricing test that charged shoppers different prices for the same items
-
Business1 week agoApple, Google and others tell some foreign employees to avoid traveling out of the country
-
Technology1 week agoChatGPT’s GPT-5.2 is here, and it feels rushed
-
Politics1 week ago‘Unlucky’ Honduran woman arrested after allegedly running red light and crashing into ICE vehicle